No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWDm | 7 | 7 | 7 | 7 | 8 | 8 | N/A | N/A |
| Operating profit | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TWDm | -129 | -120 | -266 | -260 | -231 | -258 | N/A | N/A |
| EPS reported | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Energenesis Biomedical CO.,LTD. (6657.TW)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.